The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?

In different large-scale clinic outcome trials, sodium (Na(+))/glucose co-transporter 2 (SGLT2) inhibitors showed profound cardiac- and renal-protective effects, making them revolutionary treatments for heart failure and kidney disease. Different theories are proposed according to the emerging prote...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jiang, Tian, Jiang, Sodhi, Komal, Shapiro, Joseph I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595165/
https://www.ncbi.nlm.nih.gov/pubmed/34297135
http://dx.doi.org/10.1007/s00232-021-00192-z
_version_ 1784600137952133120
author Liu, Jiang
Tian, Jiang
Sodhi, Komal
Shapiro, Joseph I.
author_facet Liu, Jiang
Tian, Jiang
Sodhi, Komal
Shapiro, Joseph I.
author_sort Liu, Jiang
collection PubMed
description In different large-scale clinic outcome trials, sodium (Na(+))/glucose co-transporter 2 (SGLT2) inhibitors showed profound cardiac- and renal-protective effects, making them revolutionary treatments for heart failure and kidney disease. Different theories are proposed according to the emerging protective effects other than the original purpose of glucose-lowering in diabetic patients. As the ATP-dependent primary ion transporter providing the Na(+) gradient to drive other Na(+)-dependent transporters, the possible role of the sodium–potassium adenosine triphosphatase (Na/K-ATPase) as the primary ion transporter and its signaling function is not explored. GRAPHIC ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-8595165
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-85951652021-11-24 The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road? Liu, Jiang Tian, Jiang Sodhi, Komal Shapiro, Joseph I. J Membr Biol Article In different large-scale clinic outcome trials, sodium (Na(+))/glucose co-transporter 2 (SGLT2) inhibitors showed profound cardiac- and renal-protective effects, making them revolutionary treatments for heart failure and kidney disease. Different theories are proposed according to the emerging protective effects other than the original purpose of glucose-lowering in diabetic patients. As the ATP-dependent primary ion transporter providing the Na(+) gradient to drive other Na(+)-dependent transporters, the possible role of the sodium–potassium adenosine triphosphatase (Na/K-ATPase) as the primary ion transporter and its signaling function is not explored. GRAPHIC ABSTRACT: [Image: see text] Springer US 2021-07-23 2021 /pmc/articles/PMC8595165/ /pubmed/34297135 http://dx.doi.org/10.1007/s00232-021-00192-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Liu, Jiang
Tian, Jiang
Sodhi, Komal
Shapiro, Joseph I.
The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?
title The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?
title_full The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?
title_fullStr The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?
title_full_unstemmed The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?
title_short The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?
title_sort na/k-atpase signaling and sglt2 inhibitor-mediated cardiorenal protection: a crossed road?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595165/
https://www.ncbi.nlm.nih.gov/pubmed/34297135
http://dx.doi.org/10.1007/s00232-021-00192-z
work_keys_str_mv AT liujiang thenakatpasesignalingandsglt2inhibitormediatedcardiorenalprotectionacrossedroad
AT tianjiang thenakatpasesignalingandsglt2inhibitormediatedcardiorenalprotectionacrossedroad
AT sodhikomal thenakatpasesignalingandsglt2inhibitormediatedcardiorenalprotectionacrossedroad
AT shapirojosephi thenakatpasesignalingandsglt2inhibitormediatedcardiorenalprotectionacrossedroad
AT liujiang nakatpasesignalingandsglt2inhibitormediatedcardiorenalprotectionacrossedroad
AT tianjiang nakatpasesignalingandsglt2inhibitormediatedcardiorenalprotectionacrossedroad
AT sodhikomal nakatpasesignalingandsglt2inhibitormediatedcardiorenalprotectionacrossedroad
AT shapirojosephi nakatpasesignalingandsglt2inhibitormediatedcardiorenalprotectionacrossedroad

Ejemplares similares